Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management

References

• MilaneziFCarvalhoSSchmittFCEGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapyExpert Rev Mol Diagn20088441743418598224
   PubMed Web of Science ®Google Scholar
• O’BrienCCavetGPanditaAFunctional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancerCancer Res200868135380538918593940
   PubMed Web of Science ®Google Scholar
• JemalACancer Statistics, 2009CA Cancer J Clin20095922524919474385
   PubMed Web of Science ®Google Scholar
• RebbeckTRTTroxelABNormanSPharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer riskAm J Epidemiol2007166121392139917827444
   PubMed Web of Science ®Google Scholar
• TanSHLeeSCGohBCWongJPharmacogenetics in breast cancer therapyClin Cancer Res200814248027804119088019
   PubMed Web of Science ®Google Scholar
• HuangRSRatainMJPharmacogenetics and pharmacogenomics of anticancer agentsCA Cancer J Clin2009591425519147868
   PubMed Web of Science ®Google Scholar
• EvansWEMcLeodHLPharmacogenomics – drug disposition, drug targets, and side effectsN Engl J Med2003348653854912571262
   PubMed Web of Science ®Google Scholar
• ZhangWHuangRSDolanMEIntegrating epigenomics into pharmacogenomics studiesPharmacogenomics Pers Med20081714
   Google Scholar
• IngleJNPharmacogenomics of tamoxifen and aromatase inhibitorsCancer2008112Suppl 369569918072234
   PubMed Web of Science ®Google Scholar
• WeinshilboumRPharmacogenomics of endocrine therapy in breast cancerAdv Exp Med Biol200863022023118637494
   PubMed Web of Science ®Google Scholar
• GradhandUKKimRBPharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2)Drug Metab Rev200840231735418464048
   PubMed Web of Science ®Google Scholar
• KimSMisraASNP genotyping: technologies and biomedical applicationsAnnu Rev Biomed Eng2007928932017391067
   PubMed Web of Science ®Google Scholar
• ShimizuCFujiwaraYPersonalized systemic treatment for breast cancer patients: is it a reality?Breast Cancer200815214114418274835
   PubMed Web of Science ®Google Scholar
• BlackhallFHHowellSNewmanBPharmacogenetics in the management of breast cancer – prospects for individualised treatmentFam Cancer20065215115716736284
   PubMed Web of Science ®Google Scholar
• LymberisSCParharPKKatsoulakisEFormentiSCPharmacogenomics and breast cancerPharmacogenomics200451315514683419
   PubMed Web of Science ®Google Scholar
• Sims-MourtadaJIzzoJGAjaniJChaoKSSonic hedgehog promotes multiple drug resistance by regulation of drug transportOncogene20072638P5674P5679
   PubMed Web of Science ®Google Scholar
• BrauchHPharmacogenomics of tamoxifen therapyClin Chem200955101770178219574470
   PubMed Web of Science ®Google Scholar
• BriestSStearnsVTamoxifen metabolism and its effect on endocrine treatment of breast cancerClin Adv Hematol Oncol20097318519219398943
   PubMedGoogle Scholar
• GoetzMPKamalAAmesMMTamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug responseClin Pharmacol Ther200883116016617882159
   PubMed Web of Science ®Google Scholar
• StearnsVJohnsonMDRaeJMActive tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetineJ Natl Cancer Inst200395231758176414652237
   PubMed Web of Science ®Google Scholar
• SchrothWAntoniadouLFritzPBreast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypesJ Clin Oncol200725335187519318024866
   PubMed Web of Science ®Google Scholar
• AmirimaniBIncreased transcriptional activity of the CYP3A4*1B promoter variantEnviron Mol Mutagen200342429930514673875
   PubMed Web of Science ®Google Scholar
• HustertEThe genetic determinants of the CYP3A5 polymorphismPharmacogenetics200111977377911740341
   PubMedGoogle Scholar
• KuehlPSequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expressionNat Genet200127438339111279519
   PubMed Web of Science ®Google Scholar
• GoetzMPPharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesJ Clin Oncol200523369312931816361630
   PubMed Web of Science ®Google Scholar
• JinYCYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentJ Natl Cancer Inst2005971303915632378
   PubMed Web of Science ®Google Scholar
• TuckerANPolymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patientsCancer Lett20052171617215596297
   PubMed Web of Science ®Google Scholar
• WegmanPGenetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancerBreast Cancer Res200791R717244352
   PubMed Web of Science ®Google Scholar
• NagarSWaltherSBlanchardRLSulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradationMol Pharmacol20066962084209216517757
   PubMed Web of Science ®Google Scholar
• OhtakeEFrequency distribution of phenol sulfotransferase 1A1 activity in platelet cells from healthy Japanese subjectsEur J Pharm Sci200628427227716621480
   PubMed Web of Science ®Google Scholar
• RaftogianisRBPhenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotypeBiochem Biophys Res Commun199723912983049345314
   PubMed Web of Science ®Google Scholar
• NowellSAssociation between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapyJ Natl Cancer Inst200294211635164012419790
   PubMedGoogle Scholar
• WegmanPGenotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patientsBreast Cancer Res200573R284R29015987423
   PubMed Web of Science ®Google Scholar
• HebbringSJAdjeiAABaerJLHuman SULT1A1 gene: copy number differences and functional implicationsHum Mol Genet200716546347017189289
   PubMed Web of Science ®Google Scholar
• NowellSAAssociation of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patientsBreast Cancer Res Treat200591324925815952058
   PubMed Web of Science ®Google Scholar
• GoetzMPThe impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifenBreast Cancer Res Treat2007101111312117115111
   PubMed Web of Science ®Google Scholar
• GoetzMPKamalAAmesMMTamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug responseClin Pharmacol Ther200883116016617882159
   PubMed Web of Science ®Google Scholar
• GallacchiPIncreased expression of estrogen-receptor exon-5-deletion variant in relapse tissues of human breast cancerInt J Cancer199879144489495357
   PubMed Web of Science ®Google Scholar
• JirstromKAdverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplificationCancer Res200565178009801616140974
   PubMed Web of Science ®Google Scholar
• BostnerJAmplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancerOncogene200726496997700517486065
   PubMed Web of Science ®Google Scholar
• LundgrenKGene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancerBreast Cancer Res2008105R8118823530
   PubMed Web of Science ®Google Scholar
• WegmanPp53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patientsPharmacogenet Genomics200616534735116609366
   PubMed Web of Science ®Google Scholar
• KimHSOverexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapyBreast Cancer Res Treat2009121377778819806450
   PubMed Web of Science ®Google Scholar
• HadjiPPractical guidance for the management of aromatase inhibitor-associated bone lossAnn Oncol20081981407141618448451
   PubMed Web of Science ®Google Scholar
• YamamotoDSVialePHUpdate on identifying and managing osteoporosis in women with breast cancerClin J Oncol Nurs2009135E18E2919793700
   PubMed Web of Science ®Google Scholar
• HiscoxSDaviesELBarrett-LeePAromatase inhibitors in breast cancerMaturitas200963427527919577386
   PubMed Web of Science ®Google Scholar
• MaCXHuman aromatase: gene resequencing and functional genomicsCancer Res20056523110711108216322257
   PubMed Web of Science ®Google Scholar
• ColomerRA single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinomaClin Cancer Res200814381181618245543
   PubMed Web of Science ®Google Scholar
• Lopez-GuerreroJAGarcia-CasadoZGuerrero-ZotanoALCorroboration of polymorphisms in the aromatase (CYP19A1) gene with response to neo-adjuvant therapy with letrozole in postmenopausal women with stages II-II ER/PgR-positive breast cancerProc Am Soc Clin Oncol200725602
   Google Scholar
• RianchoJAAromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral densityBone200536591792515794932
   PubMed Web of Science ®Google Scholar
• MarshSMcLeodHLPharmacogenetics and oncology treatment for breast cancerExpert Opin Pharmacother200782P119P127
   PubMed Web of Science ®Google Scholar
• ZarrabeitiaMTA common polymorphism in the 5′-untranslated region of the aromatase gene influences bone mass and fracture riskEur J Endocrinol2004150569970415132727
   PubMed Web of Science ®Google Scholar
• AcharyaCRHsuDSAndersCKGene expression signatures, clinicopathological features, and individualized therapy in breast cancerJAMA2008299131574158718387932
   PubMed Web of Science ®Google Scholar
• GligorovJLotzJPPreclinical pharmacology of the taxanes: implications of the differencesOncologist20049Suppl 23815161985
   PubMed Web of Science ®Google Scholar
• BrunoRAlpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxelClin Cancer Res2003931077108212631610
   PubMed Web of Science ®Google Scholar
• HansenJELarsenVABog-HansenTCThe microheterogeneity of alpha 1-acid glycoprotein in inflammatory lung disease, cancer of the lung and normal healthClin Chim Acta1984138141476713687
   PubMed Web of Science ®Google Scholar
• NakamuraTAlpha 1-acid glycoprotein expression in human leukocytes: possible correlation between alpha 1-acid glycoprotein and inflammatory cytokines in rheumatoid arthritisInflammation199317133458432561
   PubMed Web of Science ®Google Scholar
• IscanMThe expression of cytochrome P450 enzymes in human breast tumours and normal breast tissueBreast Cancer Res Treat2001701475411767004
   PubMed Web of Science ®Google Scholar
• McFadyenMCCytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancerBr J Cancer200185224224611461084
   PubMed Web of Science ®Google Scholar
• McKayJAExpression of cytochrome P450 CYP1B1 in breast cancerFEBS Lett199537422702727589551
   PubMed Web of Science ®Google Scholar
• MurrayGITumor-specific expression of cytochrome P450 CYP1B1Cancer Res19975714302630319230218
   PubMed Web of Science ®Google Scholar
• MarshSSomloGLiXPharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancerPharmacogenomics J20077536236517224914
   PubMed Web of Science ®Google Scholar
• ChangJCGene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patientsBreast Cancer Res Treat2008108223324017468949
   PubMed Web of Science ®Google Scholar
• IslaDSingle nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancerAnn Oncol20041581194120315277258
   PubMed Web of Science ®Google Scholar
• ManoMVinorelbine in the management of breast cancer: new perspectives, revived role in the era of targeted therapyCancer Treat Rev200632210611816473470
   PubMed Web of Science ®Google Scholar
• PanJHMDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancerRespiration200875438038517851225
   PubMed Web of Science ®Google Scholar
• PanJHCYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancerActa Oncol200746336136617450472
   PubMed Web of Science ®Google Scholar
• WongMPredictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancerJ Clin Oncol200624162448245516651648
   PubMed Web of Science ®Google Scholar
• SchottAFCombination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing schemeCancer Chemother Pharmacol200658112913516283312
   PubMed Web of Science ®Google Scholar
• de JongeMEClinical pharmacokinetics of cyclophosphamideClin Pharmacokinet200544111135116416231966
   PubMed Web of Science ®Google Scholar
• HassanMA mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patientsBr J Clin Pharmacol199948566967710594468
   PubMed Web of Science ®Google Scholar
• GheuensESleePHde BruijnEABioavailability of cyclophosphamide in the CMF regimenOnkologie19901332032062204007
   PubMedGoogle Scholar
• PowisGEffect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patientsCancer Chemother Pharmacol19872032192223315280
   PubMed Web of Science ®Google Scholar
• PruthiSA multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerationsMayo Clin Proc20078291131114017803883
   PubMed Web of Science ®Google Scholar
• SuHIAssociation of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivorsFertil Steril200994264565419376514
   PubMed Web of Science ®Google Scholar
• PetrosWPAssociations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancerJ Clin Oncol200523256117612516087946
   PubMed Web of Science ®Google Scholar
• van SchaikRHCancer treatment and pharmacogenetics of cytochrome P450 enzymesInvest New Drugs200523651352216267627
   PubMed Web of Science ®Google Scholar
• NakajimaMGenetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patientsPharmacogenet Genomics200717643144517502835
   PubMed Web of Science ®Google Scholar
• EkhartCInfluence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamidePharmacogenet Genomics200818651552318496131
   PubMed Web of Science ®Google Scholar
• HeinemannVComparison of the cellular pharmacokinetics and toxicity of 2′, 2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosineCancer Res19884814402440313383195
   PubMed Web of Science ®Google Scholar
• PlunkettWHuangPGandhiVPreclinical characteristics of gemcitabineAnticancer Drugs19956Suppl 67138718419
   PubMed Web of Science ®Google Scholar
• SugiyamaEPharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphismJ Clin Oncol2007251324217194903
   PubMed Web of Science ®Google Scholar
• FukunagaAKIdentification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathwayPharmacogenomics J20044530731415224082
   PubMed Web of Science ®Google Scholar
• RhaSYAn association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patientsOncologist200712662263017602053
   PubMed Web of Science ®Google Scholar
• YeoAWSoongRCSchuahBYCorrelation of RRM1 promoter region single nucleotide polymorphisms (SNPs) with response and outcome in breast cancer patients treated with gemcitabine-based chemotherapy [abstract 14513]J Clin Oncol20082618165637
   PubMed Web of Science ®Google Scholar
• LambaJKPharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variantsJ Pharmacol Exp Ther2007323393594517855478
   PubMed Web of Science ®Google Scholar
• NishiyamaMEEguchiHPharmacokinetics and pharmacogenomics in gastric cancer chemotherapyAdv Drug Deliv Rev200861540240719133303
   PubMed Web of Science ®Google Scholar
• MartinDNAssociation of MTHFR gene polymorphisms with breast cancer survivalBMC Cancer2006625717069650
   PubMed Web of Science ®Google Scholar
• ShrubsoleMJMTHFR genotypes and breast cancer survival after surgery and chemotherapy: a report from the Shanghai Breast Cancer StudyBreast Cancer Res Treat2005911737915868433
   PubMed Web of Science ®Google Scholar
• WattersJWMcLeodHLCancer pharmacogenomics: current and future applicationsBiochim Biophys Acta2003160329911112618310
   PubMed Web of Science ®Google Scholar
• PareLInfluence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapyAnticancer Drugs200718782182517581305
   PubMed Web of Science ®Google Scholar
• RibellesNA carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progressionCurr Drug Metab20089433634318473752
   PubMed Web of Science ®Google Scholar
• TordaiAWWangJAndreFEvaluation of biological pathways involved in chemotherapy response in breast cancerBreast Cancer Res2008102R3718445275
   PubMed Web of Science ®Google Scholar
• RyuJSAssociation between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapyLung Cancer200444331131615140544
   PubMed Web of Science ®Google Scholar
• TibaldiCCorrelation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patientsClin Cancer Res20081461797180318347182
   PubMed Web of Science ®Google Scholar
• FanLGenotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicityPharmacogenet Genomics200818762163118551042
   PubMed Web of Science ®Google Scholar
• LalSInfluence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patientsCancer Sci200899481682318377430
   PubMed Web of Science ®Google Scholar
• KafkaAPolymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancerInt J Oncol20032251117112112684679
   PubMed Web of Science ®Google Scholar
• RodriguesFFCorrelation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancerGenet Mol Res20087117718318393221
   PubMed Web of Science ®Google Scholar
• EngenRMEthnic differences in pharmacogenetically relevant genesCurr Drug Targets20067121641164817168839
   PubMed Web of Science ®Google Scholar
• LalSNovel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patientsPharmacogenomics20078656757517559346
   PubMed Web of Science ®Google Scholar
• InnocentiFEpirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7Drug Metab Dispos200129568669211302935
   PubMed Web of Science ®Google Scholar
• FagerholmRNAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancerNat Genet200840784485318511948
   PubMed Web of Science ®Google Scholar
• HubackovaMNAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinicopathological characteristics of human mammary tumorsPharmacogenet Genomics200919750551219494791
   PubMed Web of Science ®Google Scholar
• HeistRSChristianiDEGFR-targeted therapies in lung cancer: predictors of response and toxicityPharmacogenomics2009101596819102716
   PubMed Web of Science ®Google Scholar
• JinQEstevaFJCross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancerJ Mammary Gland Biol Neoplasia200813448549819034632
   PubMed Web of Science ®Google Scholar
• PayneREYagueESladeMJMeasurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patientsPharmacogenomics2009101515719102715
   PubMed Web of Science ®Google Scholar
• BenusiglioPRFocus on ERBB2Pharmacogenomics20089782582818597646
   PubMed Web of Science ®Google Scholar
• MusolinoAImmunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancerJ Clin Oncol200826111789179618347005
   PubMed Web of Science ®Google Scholar
• AspinallMGHamermeshRGRealizing the promise of personalized medicineHarv Bus Rev2007851010811716517972499
   PubMed Web of Science ®Google Scholar
• GlinskyGVHigashiyamaTGlinskiiABClassification of human breast cancer using gene expression profiling as a component of the survival predictor algorithmClin Cancer Res20041072272228315073102
   PubMed Web of Science ®Google Scholar
• SillonGJolyYFeldmanSAvardDAn ethical and legal overview of pharmacogenomics: perspectives and issuesMed Law200827484385719202860
   PubMedGoogle Scholar
• LeeSSMudaliarAMedicine. Racing forward: the Genomics and Personalized Medicine ActScience2009323591234219150830
   PubMed Web of Science ®Google Scholar
• PendergastMKRegulatory agency consideration of pharmacogenomicsExp Biol Med (Maywood)2008233121498150318849547
   PubMed Web of Science ®Google Scholar
• NyikaAEthical and practical challenges surrounding genetic and genomic research in developing countriesActa Tro2009112Suppl 1S21S31
   PubMedGoogle Scholar
• MeckleyLMGudgeonJMAndersonJLWilliamsMSVeenstraDLA policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testingPharmacoeconomics2010281617420014877
   PubMed Web of Science ®Google Scholar
• KirkRJHungJLHornerSRPerezJTImplications of pharmacogenomics for drug developmentExp Biol Med (Maywood)2008233121484149718849536
   PubMed Web of Science ®Google Scholar